FDA
-
-
-
-
-
-
-
Alpha Tau Medical (DRTS) Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT for Patients with Recurrent Glioblastoma Multiforme
-
-
-
-
-
-
-
Alpha Tau Medical (DRTS) Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT in Recurrent Cutaneous SCC
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

